Alfuzosin, an a1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects

Ahtoy, P; Chrétien, Pierre; Dupain, Thibaut; Rauch, Christoph; Rouchouse, A.; Delfolie, A.

doi:10.5414/cpp40289

Cited by 14 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That study found no significant difference in change of IPSS between groups [15] . In addition, improvement was obvious with alfuzosin 2.5 mg TID compared to alfuzosin 10 mg OD [14] . This suggested that the C max of ␣ 1 -blockers contributes to the efficacy of treatment for objective parameters, but the efficacy of ␣ 1 -blockers has to be considered not only in terms of relationships to plasma concentrations but also to prostatic concentrations.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

A Prospective, Randomized, Controlled, Multicenter Study of Naftopidil for Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 75 mg Once Daily in the Evening Compared to 25 mg Thrice Daily

et al. 2010

View full text Add to dashboard Cite

Introduction: We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/male LUTS). Patients and Methods: A total of 80 patients with BPH/male LUTS who had an International Prostate Symptom Score (IPSS) ≧8 and IPSS quality of life (QoL) ≧2 were enrolled and randomly administered naftopidil for 8 weeks at either 75 mg once daily (OD) in the evening (group O; n = 41) or 25 mg thrice daily (TID) in the morning, afternoon and evening (group T; n = 39). Results: IPSS total score, IPSS-QoL and BPH impact index (BII) were significantly improved for both groups at 8 weeks after starting treatment compared to baseline. IPSS total score and daytime and 24-hour voiding frequencies were significantly improved at 8 weeks after starting treatment for group O in comparison to group T. Group O showed a significantly better degree of change in BII in comparison to group T. Conclusions: Naftopidil 75 mg OD in the evening was better tolerated than naftopidil 25 mg TID for the objective parameter and BII.

show abstract

Section: Discussionmentioning

confidence: 90%

“…The pharmacokinetics of extended-release (ER) alfuzosin 10 mg OD are totally different from those of 2.5 mg TID [14] . The C max of alfuzosin 2.5 mg TID is higher and is reached earlier than that of ER alfuzosin 10 mg OD, which is still as effective as 2.5 mg TID [15] .…”

Section: Discussionmentioning

confidence: 99%

A Prospective, Randomized, Controlled, Multicenter Study of Naftopidil for Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 75 mg Once Daily in the Evening Compared to 25 mg Thrice Daily

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The improved cardiovascular tolerability of alfuzosin 10 mg once daily compared with that of the immediate‐release alfuzosin is probably related to the pharmacokinetics of the new once‐daily formulation (i.e. delayed and lower peak plasma concentration) [21].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia

Nordling

2005

BJU International

View full text Add to dashboard Cite

were also compared for Q max . Pair-wise comparisons were conducted using the Dunnett correction for quantitative variables and Bonferroni-Holm correction for categorical variables, allowing for multiple treatment group comparisons. RESULTSAlfuzosin 10 mg significantly improved urinary tract symptoms compared with placebo, with a mean ( SD ) change from baseline in the IPSS of -6.5 (5.2) vs -4.6 (5.8) for placebo (adjusted P = 0.007); there was a trend toward a difference between alfuzosin 15 mg, with a mean ( SD ) change from baseline in IPSS of -6.0 (5.6), and placebo (adjusted P = 0.050). The mean change from baseline in IPSS with tamsulosin 0.4 mg, at -6.5 (5.6), vs placebo was also significant (adjusted P = 0.014). The median change from baseline in Q max was significantly increased with both alfuzosin doses and with tamsulosin (all adjusted P = 0.02 vs placebo). Both doses of alfuzosin were well tolerated, with dizziness the most frequent adverse event (placebo, 4%; alfuzosin 10 mg, 6%; 15 mg, 7%; tamsulosin, 2%); the respective incidence rates of sexual function adverse events were 0%, 3%, 1% and 8%. CONCLUSIONTreatment with alfuzosin 10 mg significantly improved urinary symptoms and Q max compared with placebo and was well tolerated. There were also significant improvements over placebo with the active reference, tamsulosin 0.4 mg. The incidence of sexual function adverse events was higher with tamsulosin than with placebo. The benefit-to-risk profile of alfuzosin 10 mg once daily appeared to be reduced with a higher dose (15 mg).

show abstract

“…12 The onset of this improvement in Q max correlated with the previously reported peak plasma concentration of alfuzosin. 13 The present study describes the effects of alfuzosin 10 mg q.d. versus placebo on erectile and ejaculatory function in men with symptomatic BPH.…”

Section: Introductionmentioning

confidence: 97%

Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia

2007

View full text Add to dashboard Cite

We evaluated the effects of extended-release alfuzosin HCl 10 mg once daily (q.d.) on sexual function in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). In a randomized, double-blind, placebo-controlled study of men aged Z50 years, after a 28-day placebo run-in period, patients were randomized to receive alfuzosin 10 mg q.d. or matching placebo for 28 days. The mean change from baseline (day 1) in sexual function on day 29 was assessed using the Danish Prostate Symptom Score Sex (DAN-PSSsex) questionnaire. A total of 372 patients were randomized to receive alfuzosin (n ¼ 186) or placebo (n ¼ 186), with 355 completing the study. At baseline, 64% of the patients reported erectile dysfunction (ED) and 63% reported ejaculatory dysfunction (EjD). For the 320 patients who completed the DAN-PSSsex, alfuzosin treatment was associated with a significant improvement in the mean change from baseline in erectile function on day 29 compared with placebo (P ¼ 0.02). No significant difference was observed between the two treatment groups in the mean change from baseline in ejaculatory function on day 29. For patients with ED at baseline, a marginal improvement in erectile function was demonstrated with alfuzosin treatment (P ¼ 0.09 vs placebo). For patients with EjD at baseline, the mean change from baseline in ejaculatory function with alfuzosin was comparable to that with placebo. Dizziness was the most common adverse event with alfuzosin treatment (5 vs 0% with placebo), with other adverse events reported with comparable frequency in both treatment groups. After 1 month of treatment, alfuzosin 10 mg q.d. significantly improved erectile function in men with lower urinary tract symptoms/ benign prostatic hypertrophy and had no adverse effect on ejaculatory function.

show abstract

Alfuzosin, an a1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects

Cited by 14 publications

References 0 publications

A Prospective, Randomized, Controlled, Multicenter Study of Naftopidil for Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 75 mg Once Daily in the Evening Compared to 25 mg Thrice Daily

A Prospective, Randomized, Controlled, Multicenter Study of Naftopidil for Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 75 mg Once Daily in the Evening Compared to 25 mg Thrice Daily

Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia

Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia

Contact Info

Product

Resources

About